Effect of dexamethason on the incidence of detubation failure in children

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN54608329

Enrollment

157

Registered

2005-12-20

Start date

2004-01-01

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mechanical ventilation, complications Respiratory Ventilation

Interventions

Intervention: Dexamethason 6 x 0.5 mg/kg intravenous (i.v.) every six hours (max 10 mg dose) first dose six to 12 hours prior to detubation. Placebo: Saline (NaCl 0.9%)

Eligibility

Inclusion criteria

Inclusion criteria: 1. Aged four weeks to four years 2. Intubated more than 24 hours 3. Informed consent

Exclusion criteria

Exclusion criteria: 1. Known with one of the following diseases: a. peptic ulcurs b. diabetes mellitus c. osteoporosis d. adrenal insufficiency e. hypertension f. systemic yeast infection g. tuberculosis h. sepsis 2. Glucocorticoid use the week before detubation 3. Intubation for laryngotracheal infection 4. Mechanical ventilation for upper airway obstruction 5. Down syndrome

Design outcomes

Primary

Measure	Time frame
Detubation failure	—

Secondary

Measure	Time frame
1. Use of other therapies to reduce upper airway obstruction (epinephrin, beclomethasone) 2. Croup score 3. Supplemental oxygen 4. Adverse effects of dexamethason: hypertension, gastro-intestinal tract bleeding, hyperglycaemia	—

Countries

Netherlands

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026